People: Biospecifics Technologies Corp (BSTC.W)
BSTC.W on CBOE When Trading NASDAQ Global Select Market
16.09USD
14 Jun 2013
16.09USD
14 Jun 2013
Price Change (% chg)
$-0.05 (-0.31%)
$-0.05 (-0.31%)
Prev Close
$16.14
$16.14
Open
$16.09
$16.09
Day's High
$16.09
$16.09
Day's Low
$16.09
$16.09
Volume
100
100
Avg. Vol
62
62
52-wk High
$20.49
$20.49
52-wk Low
$13.02
$13.02
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Thomas Wegman |
57 | 2009 | President, Principal Executive Officer, Principal Financial Officer, Director |
Mark Wegman |
62 | 2007 | Director |
Toby Wegman |
77 | 2007 | Director |
Paul Gitman |
71 | 1990 | Independent Director |
George Gould |
74 | 2011 | Independent Director |
Henry Morgan |
91 | 1990 | Independent Director |
Michael Schamroth |
72 | 2004 | Independent Director |
Biographies
| Name | Description |
|---|---|
Thomas Wegman |
Mr. Thomas L. Wegman is President, Principal Executive Officer, Principal Financial Officer, Director of Biospecifics Technologies Corp. He has served as President since October 17, 2005. Prior to such appointment, he served as the Executive Vice President of the Company. Effective in 1994, Mr. Wegman became a director on the Board of the Company and has served as such since that time. He has over 30 years of experience in the bio-pharmaceutical industry that encompasses managing company operations and drug development, licensing, and registration. From 1978 thru 1983, Mr. Wegman managed the production, marketing and foreign registration activities related to an avian vaccine business. Mr. Wegman has been instrumental in licensing technologies from universities for use by the Company. He is the author of a number of U.S. and foreign patents in the life sciences field. Mr. Wegman received his B.A. from Boston University in 1977. |
Mark Wegman |
Dr. Mark N. Wegman, Ph.D., is Director of Biospecifics Technologies Corp., since June 25, 2007. He joined International Business Machines (“IBM”) in 1975 where Dr. Wegman is currently Chief Scientist Software Technology with world wide responsibilities in IBM’s Research laboratories. Dr. Wegman is recognized for his contributions to computer algorithms and compiler optimization that have deeply influenced many areas of computer science and practice. This work was recognized by the Special Interest Group On Programming Languages in 2006 with its Programming Languages Achievement Award. He is an IBM Fellow, which is IBM’s highest technical honor, and a Fellow of the ACM and the IEEE. He is also a member of the National Academy of Engineering. Dr. Wegman is the author of over 30 publications in the field of Computer Science. Dr. Wegman received his doctorate in Computer Science from the University of California at Berkeley. |
Toby Wegman |
Ms. Toby Wegman is Director of Biospecifics Technologies Corp., since June 25, 2007. Ms. Wegman is the widow of former CEO and Chairman, Edwin H. Wegman. Ms. Wegman has had a range of business-related work experiences. For five years she owned and operated a women’s apparel business and prior to that managed a women’s retail clothing operation. She had also been actively involved in the management of Edwin H. Wegman’s business interests and finances for many years. Ms. Wegman is a member of the Lion of Judah, and a lifetime member of both the National Council of Jewish Women and HADASSAH. |
Paul Gitman |
Dr. Paul A. Gitman, M.D., is Independent Director of Biospecifics Technologies Corp., since 1990. He is board certified by the American Board of Internal Medicine and the American Board of Quality Assurance and Utilization Review. Following 25 years in private medical practice he joined the fulltime faculty of Long Island Jewish Medical Center where he was Medical Director and later Vice President of Medical Affairs for the North Shore Long Island Jewish Health System until 2009. Dr. Gitman is currently an Associate Professor of Medicine at Albert Einstein College of Medicine as well as the Chairman of the Medical Society of the State of New York’s Committee for Physician’s Health. He has served on the New York State Board of Medicine for 10 years and on various New York State Committees and Task Forces. He is past President of both the New York Chapter of the American College of Physicians and the Medical Society of the County of Queens. Dr. Gitman received his medical degree from Boston University School of Medicine. |
George Gould |
Mr. George M. Gould, Esq., is Independent Director of BioSpecifics Technologies Corp., since December 6, 2011. Mr. Gould is a practicing attorney and currently serves as a Principal of George M. Gould, LLC and of counsel to Gibbons PC, where he specializes in biotechnology and pharmaceutical licensing and patent law. He has over 40 years of experience in licensing with pharmaceutical as well as start-up biotech companies. Mr. Gould was employed at Hoffmann-La Roche Inc. from 1968 to 1996, and at the time of his retirement from the company in 1996, he was serving as Vice President of Licensing and Corporate Development and Chief Patent Counsel. Prior to joining Hoffmann-La Roche, he was a Senior Patent Attorney at Esso Research & Engineering Co. for 6 years and worked as an organic chemist at Merck & Co., Inc. for 3 years. He has also served as an adjunct professor at Seton Hall University School of Law and as a lecturer at Rutgers University School of Business. Mr. Gould has previously served as a member of the Board of Tapestry Pharmaceuticals, the Board of Supratek Pharma Inc., the Board of AngioGenex Inc., and the Board of Protein Design Labs, Inc. He earned his bachelors degree in organic chemistry at The Johns Hopkins University in 1958 and conducted his graduate studies in chemistry at New York University from 1958 to 1960. Mr. Gould received his J.D. from Columbia University School of Law in 1963 and his L.L.M. from New York University School of Law in 1973. |
Henry Morgan |
Mr. Henry Morgan is Independent Director of Biospecifics Technologies Corp., since 1990, with the exception of a few interim months. He has been a practicing attorney for more than 50 years. Prior to his work as an attorney, he was employed in the insurance industry as an auditor and agent. His law practice is in the defense of corporations and individuals for claims asserted against them that allege professional errors and omissions, defective products, insurance coverage issues and employment related disputes. Mr. Morgan is a member of the Essex County, New Jersey State and American Bar Associations, the International Association of Defense Counsel and the Defense Research Institute. He received his B.A. and J.D. degrees from Rutgers, The State University of New Jersey. |
Michael Schamroth |
Mr. Michael Schamroth is an Independent Director of Biospecifics Technologies Corp., since February 2004. He has been a partner of M. Schamroth & Sons in New York City for over 40 years. As a principal in this fourth-generation international diamond house, Mr. Schamroth has experience in dealing with all aspects of the trade, from manufacturing to sales. He has been a member of the Diamond Manufacturers and Importers Association since 1964, and has served on the Nominating and Building Committees of the Diamond Dealers Club. In addition, Mr. Schamroth has served as a member of the Board of South Nassau Communities Hospital since 1976, the Board of the Winthrop-South Nassau University Health System since 1993 and the Board of Sound Bank of North Carolina since 2002. He has been a member of the Miami University Business Advisory Board since 1984 and served as its Chairman from 1987-1988. He received his B.S. in Business from Miami University, Oxford, Ohio. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Thomas Wegman |
302,533 |
Mark Wegman |
-- |
Toby Wegman |
-- |
Paul Gitman |
-- |
George Gould |
-- |
Henry Morgan |
-- |
Michael Schamroth |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Thomas Wegman |
225,200 | 544,948 |
Mark Wegman |
0 | 0 |
Toby Wegman |
0 | 0 |
Paul Gitman |
0 | 0 |
George Gould |
0 | 0 |
Henry Morgan |
0 | 0 |
Michael Schamroth |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
VOGEL JEFFREY KENNETH |
9,000 | $0.01 |
VOGEL JEFFREY KENNETH |
178,265 | $14.07 |
WEGMAN THOMAS L |
45,000 | $1.00 |
MORGAN HENRY |
5,425 | $1.00 |
VOGEL JEFFREY KENNETH |
9,750 | $0.01 |
WEGMAN TOBY |
963 | $18.06 |
WEGMAN TOBY |
858 | $18.15 |
WEGMAN TOBY |
142 | $18.16 |
WEGMAN TOBY |
1,000 | $18.39 |
WEGMAN TOBY |
1,076 | $18.62 |
WEGMAN TOBY |
200 | $18.63 |
WEGMAN TOBY |
1,500 | $18.26 |
WEGMAN TOBY |
100 | $18.68 |
WEGMAN TOBY |
500 | $18.62 |
WEGMAN TOBY |
1,500 | $18.21 |
WEGMAN TOBY |
101 | $17.74 |
WEGMAN TOBY |
100 | $17.40 |
WEGMAN TOBY |
5 | $17.47 |
WEGMAN TOBY |
1,395 | $17.35 |
WEGMAN TOBY |
1,000 | $16.75 |
WEGMAN TOBY |
21 | $21.10 |
WEGMAN TOBY |
100 | $17.00 |
WEGMAN TOBY |
1,000 | $16.25 |
WEGMAN TOBY |
1,025 | $15.63 |
WEGMAN TOBY |
700 | $16.53 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
